Insider Trading Alert - TIPT, RDNT And ARQL Traded By Insiders

Friday, Dec. 11, 2015, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $334.02 to $1,962,660.00.

Highlighted Stocks Traded by Insiders:

Tiptree Financial (TIPT) - FREE Research Report

Barnes Michael Gene, who is Executive Chairman at Tiptree Financial, bought 5,000 shares at $6.32 on Dec. 11, 2015. Following this transaction, the Executive Chairman owned 3.3 million shares meaning that the stake was boosted by 0.15% with the 5,000-share transaction.

The shares most recently traded at $6.37, up $0.05, or 0.86% since the insider transaction. Historical insider transactions for Tiptree Financial go as follows:

  • 4-Week # shares bought: 34,500
  • 12-Week # shares bought: 129,190
  • 24-Week # shares bought: 239,221

The average volume for Tiptree Financial has been 38,000 shares per day over the past 30 days. Tiptree Financial has a market cap of $218.6 million and is part of the financial sector and insurance industry. Shares are down 26.79% year-to-date as of the close of trading on Friday.

TipTree Financial Inc., formerly Care Investment Trust, operates as a real estate investment trust (REIT). It engages in originating and acquiring healthcare-related real estate and commercial mortgage debt. The stock currently has a dividend yield of 1.6%.

Exclusive Offer: Get the latest Stock Analysis on TIPT - FREE

TheStreet Quant Ratings rates Tiptree Financial as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Tiptree Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

RadNet (RDNT) - FREE Research Report

Murdock Michael N, who is Executive Vice President at RadNet, sold 771 shares at $6.60 on Dec. 11, 2015. Following this transaction, the Executive Vice President owned 249,589 shares meaning that the stake was reduced by 0.31% with the 771-share transaction.

The shares most recently traded at $5.85, down $0.75, or 12.82% since the insider transaction. Historical insider transactions for RadNet go as follows:

  • 4-Week # shares sold: 44,187
  • 12-Week # shares sold: 44,187
  • 24-Week # shares sold: 234,617

The average volume for RadNet has been 270,100 shares per day over the past 30 days. RadNet has a market cap of $292.4 million and is part of the health care sector and health services industry. Shares are down 31.15% year-to-date as of the close of trading on Friday.

RadNet, Inc. provides outpatient diagnostic imaging services in the United States. The company has a P/E ratio of 25.4. Currently, there are 2 analysts who rate RadNet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RDNT - FREE

TheStreet Quant Ratings rates RadNet as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, weak operating cash flow and generally higher debt management risk. Get the full RadNet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Arqule (ARQL) - FREE Research Report

Pucci Paolo, who is Chief Executive Officer at Arqule, bought 7,609 shares at $2.10 on Dec. 11, 2015. Following this transaction, the Chief Executive Officer owned 254,889 shares meaning that the stake was boosted by 3.08% with the 7,609-share transaction.

The shares most recently traded at $2.11, up $0.01, or 0.57% since the insider transaction. Historical insider transactions for Arqule go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 5,000

The average volume for Arqule has been 178,100 shares per day over the past 30 days. Arqule has a market cap of $133.3 million and is part of the health care sector and drugs industry. Shares are up 75.41% year-to-date as of the close of trading on Friday.

ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. Currently, there are no analysts who rate Arqule a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARQL - FREE

TheStreet Quant Ratings rates Arqule as a sell. The area that we feel has been the company's primary weakness has been its meager revenue growth. Get the full Arqule Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%